The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Imaging in neurooncology
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000
Uhrbom, L., Nerio, E., & Holland, E. C. (2004) · Nature Medicine · doi:10.1038/nm1120 · Cited by 146
Cited by
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 368
Self-citationMolecular imaging of gliomas with PET: Opportunities and limitations
la Fougere, C., Suchorska, B., Bartenstein, P., Kreth, F.-W., & Tonn, J.-C. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor054 · Cited by 274
Laukamp, K. R., Thiele, F., Shakirin, G., Zopfs, D., Faymonville, A., Timmer, M., Maintz, D., Perkuhn, M., & Borggrefe, J. (2019) · European Radiology · doi:10.1007/s00330-018-5595-8 · Cited by 205
“…delineation challenging; (3) FLAIR signal intensities differ strongly and meningiomas can even present isointense to normal brain tissue; (4) meningiomas and surrounding tissue also present heterogenous when oedema and necrosis are present next to contrast-enhancing tumour [5, 7, 20, 43, 44].”
BackgroundNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Sonni, I., Garibotto, V., Iagaru, A., Das, D., & Massoud, T. (2018) · PET/MRI in Oncology · doi:10.1007/978-3-319-68517-5_11 · Cited by 3
Metadata
- Authors
- Jacobs, A. H., Kracht, L. W., Gossmann, A., Rüger, M. A., Thomas, A. V., Thiel, A., & Herholz, K.
- Venue
- NeuroRX
- Published
- 2005-04
- Volume
- 2
- Issue
- 2
- Pages
- 333-347
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2130019868
- Cited by
- 173
- References
- 2
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.